Academic Journals Database
Disseminating quality controlled scientific knowledge

Review of oral oxymorphone in the management of pain

ADD TO MY LIST
 
Author(s): Paul Sloan

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2008;
Issue: Issue 4;
Start page: 777;
Date: 2008;
Original page

ABSTRACT
Paul SloanUniversity of Kentucky Medical Center, Department of Anesthesiology, Lexington, KY, USAAbstract: Chronic cancer and nonmalignant pain (CNMP) is a common and major health problem afflicting approximately 40 million persons in the US. Most cancer patients, and many patients with CNMP, require opioid analgesics to obtain adequate pain relief. Oral oxymorphone is a new formulation of an existing parenteral opioid that has become available for the treatment of significant pain: acute postoperative, chronic arthritis, chronic low back, and chronic cancer pain. Oxymorphone is a typical mu-opioid agonist that is effective in both immediate- and extended-release (IR and ER) formulations. Oxymorphone is more lipid soluble than morphine, resulting in a rapid onset of action when given in tablet formulation, with a duration of action of approximately 4–6 hours in IR and 12 hours in ER preparations. Oxymorphone provides excellent pain relief for significant pain, with typical opioid side effects that are usually mild or moderate in intensity. Multiple double-blind, prospective, placebo-controlled clinical trials have demonstrated the clinical efficacy and safety of this new oral opioid preparation. Oral oxymorphone is an effective opioid that provides a new therapeutic option for the physician.Keywords: chronic pain, oxymorphone, opioids, extended-release, sustained-release, cancer pain
Affiliate Program      Why do you need a reservation system?